Display options
Share it on

J Clin Diagn Res. 2016 Nov;10(11):EC01-EC04. doi: 10.7860/JCDR/2016/19985.8840. Epub 2016 Nov 01.

Haemostatic Profile in Patients of Myeloproliferative Neoplasms-A Tertiary Care Centre Experience.

Journal of clinical and diagnostic research : JCDR

Yatendra Parashar, Rashmi Kushwaha, Ashutosh Kumar, Kamal Agarwal, U S Singh, Mili Jain, S P Verma, A K Tripathi

Affiliations

  1. Junior Resident, Department of Pathology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  2. Associate Professor, Department of Pathology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  3. Professor and Head, Department of Pathology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  4. Professor, Department of Pathology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  5. Assistant Professor, Department of Pathology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  6. Assistant Professor, Department of Clinical Hematology, King George's Medical University , Lucknow, Uttar Pradesh, India .
  7. Head of Department of Clinical Hematology, King George's Medical University , Lucknow, Uttar Pradesh, India .

PMID: 28050371 PMCID: PMC5198324 DOI: 10.7860/JCDR/2016/19985.8840

Abstract

INTRODUCTION: Patients of MPN commonly present with abnormalities in laboratory coagulation tests that are consistent with hypercoagulable state. Some individuals with MPN exhibit a pattern of exclusive bleeding or thrombotic events; many others have both bleeding and thrombosis during the course of the disease.

AIM: This study was undertaken to assess the haemostatic defects and platelet functions in patients of MPN.

MATERIALS AND METHODS: One year prospective study was conducted at a tertiary care centre in North India in Department of Pathology in collaboration with Department of Clinical Haematology. All recently diagnosed cases of MPN along with 30 age and sex matched controls were included. Patients on antiplatelet drugs, antimyeloproliferative treatment, vitamin K agonists or antagonists, OCPs, Platelet count <1,00,000/μl, high grade fever, liver disease, pregnancy were excluded from this study. All the patients underwent screening investigations like CBC, peripheral smear evaluation, BT, PT, aPTT, Protein C and S measurement (clot based assay) and aggregation studies with ADP (5μM) (Optical Aggregometry with AGGRO/LINK 8 software and CHRONOLOG 700 aggregometer).

RESULTS: In present study, 50 cases were included. There was an occult prothrombotic state, suggested by significantly (p<0.001) reduced levels of Protein C and Protein S, but no patient presented with frank thrombosis while 8 out of 50 patients had haemorrhagic manifestations ranging from subdural haematoma to pin point petechial haemorrhages. Patients of CML-CP, ET, PV, PMF, MPN-NOS showed significantly reduced maximal aggregation with ADP (5μM) when compared to control (p<0.001). MPV also showed a statistically significant increase in these patients.

CONCLUSION: Thrombohaemorrhagic complications significantly affect the morbidity and mortality of MPN patients. This can be assessed by the use of platelet aggregation studies, Protein C and S activities and other coagulation studies. Timely diagnosis of these prothrombotic/haemorrhagic states can decrease the morbidity in these patients.

Keywords: Haemorrhage; Platelet dysfunction; Thrombosis

References

  1. Am J Hematol. 2012 Mar;87(3):285-93 - PubMed
  2. Blood. 2000 Dec 15;96(13):4261-6 - PubMed
  3. Am J Hematol. 2009 Feb;84(2):102-8 - PubMed
  4. Crit Rev Oncol Hematol. 1995 Oct;20(3):203-22 - PubMed
  5. Am J Hematol. 1996 May;52(1):14-20 - PubMed
  6. Prostaglandins Leukot Med. 1983 Nov;12(3):261-72 - PubMed
  7. Thromb Haemost. 1982 Aug 24;48(1):41-5 - PubMed
  8. Cancer. 1988 Jun 15;61(12):2487-96 - PubMed
  9. Thromb Res. 1995 May 15;78(4):315-21 - PubMed
  10. Scand J Clin Lab Invest. 1993 May;53(3):281-8 - PubMed
  11. J Thromb Haemost. 2011 Nov;9(11):2208-14 - PubMed
  12. Br J Haematol. 2013 Sep;162(6):730-47 - PubMed
  13. Br J Haematol. 1988 Jan;68(1):97-101 - PubMed
  14. Thromb Haemost. 1987 Aug 4;58(2):753-7 - PubMed
  15. Best Pract Res Clin Haematol. 2006;19(3):617-33 - PubMed
  16. Am J Clin Pathol. 2005 May;123(5):772-7 - PubMed
  17. Am J Hematol. 2003 Feb;72(2):75-81 - PubMed
  18. Leukemia. 2012 Apr;26(4):563-71 - PubMed
  19. J Cell Mol Med. 2001 Jan-Mar;5(1):79-87 - PubMed
  20. J Thromb Haemost. 2005 Dec;3(12):2712-20 - PubMed
  21. Arch Pathol Lab Med. 1981 Aug;105(8):432-5 - PubMed
  22. Blood. 1978 Mar;51(3):479-86 - PubMed
  23. Thromb Res. 1981 May 15;22(4):389-97 - PubMed
  24. Thromb Haemost. 1982 Apr 30;47(2):84-9 - PubMed
  25. Am J Hematol. 2014 Nov;89(11):E200-5 - PubMed
  26. Thromb Res. 1991 Feb 1;61(3):271-8 - PubMed
  27. Br J Haematol. 1985 Jun;60(2):331-44 - PubMed
  28. Br J Haematol. 1989 Nov;73(3):369-74 - PubMed
  29. Blood. 2008 Nov 15;112(10):4061-8 - PubMed
  30. Exp Hematol. 2007 May;35(5):702-11 - PubMed
  31. Blood. 1986 Dec;68(6):1213-7 - PubMed
  32. Semin Thromb Hemost. 2014 Apr;40(3):348-58 - PubMed
  33. Clin Haematol. 1983 Feb;12(1):89-106 - PubMed
  34. Haemostasis. 1982;11(2):119-27 - PubMed

Publication Types